Geneva, April 28 -- International Clinical Trials Registry received information related to the study (ChiCTR2600122725) titled 'Efficacy and safety of topical sirolimus gel in the treatment of angioproliferative skin diseases' on April 16.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: The Second Affiliated Hospital of Xi'an Jiaotong University
Condition:
Rosacea
Intervention:
Experimental Group:Apply 0.2% sirolimus gel thinly onto the areas of hypertrophic lesions twice daily, with the total daily dosage not exceeding 800mg.
Recruitment Status: Recruiting
Phase: 4
Date of First Enrollment: 2026-04-16
Target Sample Size: Experimental Group:32;Control Group:32;
Countries of Recruitment:
China
To ...